
Resmed
ResMed is a global leader in the design, manufacture, and distribution of medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders, including sleep apnea, COPD, and other chronic diseases. The company's core business revolves around providing innovative solutions for improving the quality of life for people with respiratory conditions, holding a significant market share in the sleep apnea treatment market.
Short position
Resmed (ASX:RMD) has 0.44% of its shares on issue reported as short positions as of 5 Oct 2026, or about 2,484,851 shares. Over the past 30 days that figure has fallen 0.12 percentage points, and over 90 days it has risen 0.08 percentage points. Its highest recorded short interest was 3.10% in October 2014. RMD is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Resmed (RMD) short interest history
RMD Short Interest History
- 30-day change
- -0.12pp
- 90-day change
- +0.08pp
- 1-year change
- +0.27pp
- All-time high
- 3.10% (October 2014)
- All-time low
- 0.00% (August 2018)
Is RMD heavily shorted?
Not especially: 0.44% short interest is modest by ASX standards, ranking #337 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has RMD's short interest changed recently?
Over the past 30 days Resmed's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.44% of shares on issue.
What is the highest RMD's short interest has been?
Since 2010, Resmed's short interest peaked at 3.10% in October 2014 and bottomed at 0.00% in August 2018.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2010. See our methodology.